Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

by Manuel García-Goñi, Isabel Río-Álvarez, David Carcedo, Alba Villacampa
Published 2021-04-01

Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain

by Luis Cordero Puentes, Carlota Moya de Alarcón, David Carcedo, Jordi Ginés Rubió, Maria del Carmen Garcías de España, Laura Delgado-Ortega
Published 2018-05-01

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

by Ernest Nadal, Dolores Bautista, Luis Cabezón-Gutiérrez, Ana Laura Ortega, Héctor Torres, David Carcedo, Lucía Ruiz de Alda, J. Francisco Garcia, Paula Vieitez, Federico Rojo
Published 2021-06-01